Clinical Trial Update: An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event [Phase 4]

View source ↗

Summary

Open-label Phase 4 study assessing tolerability of ramipril in patients at high risk for major cardiovascular events; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Ramipril (ramipril)

Snippet

Sponsor: Sanofi | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED